14.10
-0.26(-1.81%)
Currency In USD
| Previous Close | 14.36 |
| Open | 14.37 |
| Day High | 14.68 |
| Day Low | 13.97 |
| 52-Week High | 17.7 |
| 52-Week Low | 9.03 |
| Volume | 231,471 |
| Average Volume | 463,237 |
| Market Cap | 1.06B |
| PE | -14.39 |
| EPS | -0.98 |
| Moving Average 50 Days | 13.06 |
| Moving Average 200 Days | 13.22 |
| Change | -0.26 |
If you invested $1000 in Zymeworks Inc. (ZYME) since IPO date, it would be worth $1,084.62 as of August 18, 2025 at a share price of $14.1. Whereas If you bought $1000 worth of Zymeworks Inc. (ZYME) shares 5 years ago, it would be worth $473.79 as of August 18, 2025 at a share price of $14.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
GlobeNewswire Inc.
Aug 11, 2025 10:00 AM GMT
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficu
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
GlobeNewswire Inc.
Jul 28, 2025 10:00 AM GMT
Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and favorable tolerability profilePhase 1 clinical trial eva
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
GlobeNewswire Inc.
Jul 17, 2025 10:00 AM GMT
Company to participate in investor conferences in July and AugustVANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunct